Apex Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Apex Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$38M	Buy	1,292,751 +82,294	+7%	+$2.29M	0.84%	54
2015 Q4	$40M	Sell	1,210,457 -10,858	-0.9%	-$354K	0.89%	47
2015 Q3	$44.1M	Buy	1,221,315 +61,874	+5%	+$2.66M	1%	39
2015 Q2	$52.2M	Buy	1,159,441 +56,318	+5%	+$2.19M	1.12%	36
2015 Q1	$33.8M	Buy	1,103,123 +516,422	+88%	+$20.1M	0.8%	53
2014 Q4	$29.8M	Buy	586,701 +536,451	+1,068%	+$24M	0.8%	52
2014 Q3	$1.99M	Buy	50,250 +5,157	+11%	+$206K	0.06%	172
2014 Q2	$1.94M	Buy	45,093 +6,338	+16%	+$242K	0.06%	174
2014 Q1	$1.55M	Buy	+38,755	New	+$1.41M	0.05%	176

Other funds holding ENTA

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Apex Capital Management's ENTA Position: Q1 2016 in Review

Apex Capital Management increased its Enanta Pharmaceuticals (ENTA) stake by 6.8% in Q1 2016, buying an estimated $2.29M and bringing the position to 1,292,751 shares worth $38M. The position accounts for 0.84% of the portfolio, ranked #54.

Apex Capital Management first reported a position in ENTA in Q1 2014 and has held it in 9 quarters since. The position peaked at $52.2M in Q2 2015. 153 funds tracked by Wall St. Rank hold ENTA as of Q1 2016.

Apex Capital Management held 1,292,751 shares of Enanta Pharmaceuticals worth $38M as of Q1 2016.
Apex Capital Management bought 82,294 Enanta Pharmaceuticals shares in Q1 2016, an estimated $2.29M.
Enanta Pharmaceuticals made up 0.84% of Apex Capital Management's portfolio in Q1 2016, its #54 holding.
Apex Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2014 and has held it in 9 quarters since.
Apex Capital Management's Enanta Pharmaceuticals position peaked at $52.2M in Q2 2015.
153 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.